Geron Q2 net loss $28.1M; IMerge Phase 3 top-line results expected early Jan 2023

GERON CORP

2022-Q2 EPS reported -$0.16 revenue$196,000

Net loss of $28.1M ($0.07 per share) vs $29.6M ($0.09) in Q2 2021; revenue $73K.
Cash and marketable securities $220M as of June 30, 2022; debt facility expanded to $125M with $50M additional non-dilutive capital available in 2023.
FY2022 GAAP operating expenses guided $155-165M; non-GAAP $140-150M.
IMerge Phase 3 top-line results in lower risk MDS on track for early Jan 2023; U.S. NDA planned H1 2023, EU MAA H2 2023.
Pipeline expansion: new studies in R/R AML and frontline MF starting H2 2022; IMpactMF interim analysis in 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.